Patricia M LoRusso

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. pmc Targeting the epidermal growth factor receptor
    B F El-Rayes
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University 48201, USA
    Br J Cancer 91:418-24. 2004
  2. doi request reprint Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Invest New Drugs 32:303-11. 2014
  3. doi request reprint Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
    Patricia LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R St, Detroit, MI, 48201, USA
    Invest New Drugs 32:160-70. 2014
  4. doi request reprint Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Patricia LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 19:3078-87. 2013
  5. doi request reprint Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 18:6101-9. 2012
  6. doi request reprint Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment
    Patricia Mucci LoRusso
    Karmanos Cancer Institute Wayne State University, Detroit, MI 48201, USA
    Oncology 84:43-56. 2013
  7. doi request reprint Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
    Sachin Gupta
    Karmanos Cancer Institute, Department of Oncology, Detroit, MI, USA
    J Natl Cancer Inst 104:1860-6. 2012
  8. doi request reprint Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
    Ian Krop
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 30:2307-13. 2012
  9. pmc Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Clin Cancer Res 18:2954-63. 2012
  10. ncbi request reprint Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
    Patricia M LoRusso
    Barbara Ann Karmanos Cancer Institute, 4100 John R 4 HWCRC, Room 4206, Detroit, MI 48201, USA
    J Clin Oncol 23:5281-93. 2005

Research Grants

  1. Phase I Clinical Trials of New Anticancer Agents
    Patricia LoRusso; Fiscal Year: 2007

Detail Information

Publications58

  1. pmc Targeting the epidermal growth factor receptor
    B F El-Rayes
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University 48201, USA
    Br J Cancer 91:418-24. 2004
    ..Future issues in the development of EGFR inhibitors include the identification of biologic predictors of response, combination with other targeted agents, and their utilisation in earlier stage malignancies...
  2. doi request reprint Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Invest New Drugs 32:303-11. 2014
    ....
  3. doi request reprint Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
    Patricia LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R St, Detroit, MI, 48201, USA
    Invest New Drugs 32:160-70. 2014
    ..This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF) distribution, and preliminary clinical activity of the receptor tyrosine kinase inhibitor TAK-285...
  4. doi request reprint Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Patricia LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 19:3078-87. 2013
    ..This first-in-human study of U3-1287 (NCT00730470), a fully human anti-HER3 monoclonal antibody, evaluated its safety, tolerability, and pharmacokinetics in patients with advanced solid tumor...
  5. doi request reprint Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 18:6101-9. 2012
    ....
  6. doi request reprint Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment
    Patricia Mucci LoRusso
    Karmanos Cancer Institute Wayne State University, Detroit, MI 48201, USA
    Oncology 84:43-56. 2013
    ..In this review, we consider the translation of mTOR inhibitors from laboratory studies to large clinical trials, driven by a rational understanding of the role of mTOR in the processes that underlie breast cancer tumorigenesis...
  7. doi request reprint Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
    Sachin Gupta
    Karmanos Cancer Institute, Department of Oncology, Detroit, MI, USA
    J Natl Cancer Inst 104:1860-6. 2012
    ..We analyzed patient outcome results in MTA phase I trials at multiple institutions throughout North America sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program...
  8. doi request reprint Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
    Ian Krop
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 30:2307-13. 2012
    ..Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of MK-0752...
  9. pmc Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Clin Cancer Res 18:2954-63. 2012
    ..This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to inform dosing recommendations in these special populations...
  10. ncbi request reprint Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
    Patricia M LoRusso
    Barbara Ann Karmanos Cancer Institute, 4100 John R 4 HWCRC, Room 4206, Detroit, MI 48201, USA
    J Clin Oncol 23:5281-93. 2005
    ....
  11. doi request reprint Translating clinical trials into meaningful outcomes
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 16:5951-5. 2010
    ..The challenge today is to develop new approaches to translate scientific discovery into cost-effective and meaningful improvements in cancer outcomes...
  12. ncbi request reprint Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
    Patricia LoRusso
    Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI, 48201, USA
    Invest New Drugs 26:455-62. 2008
    ..Hypertension was the most common related grade 3 event (21%). No grade 4 or 5 treatment-related adverse events occurred...
  13. doi request reprint Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study
    Patricia LoRusso
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Invest New Drugs 29:1395-405. 2011
    ..This phase I, single-center, dose-finding study was designed primarily to investigate the safety and pharmacokinetics (PK) of cediranib with various anticancer regimens in patients with advanced solid tumors...
  14. doi request reprint Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 16:5956-62. 2010
    ....
  15. doi request reprint Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
    ..This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126...
  16. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 16:1924-37. 2010
    ..To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901, a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor in advanced cancer patients...
  17. doi request reprint An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 16:1710-8. 2010
    ..A final article summarizes recommendations for the design and conduct of phase II studies...
  18. doi request reprint Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors
    Patricia LoRusso
    Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 68:1377-85. 2011
    ....
  19. ncbi request reprint Toward evidence-based management of the dermatologic effects of EGFR inhibitors
    Patricia LoRusso
    Phase I Clinical Trial Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
    Oncology (Williston Park) 23:186-94. 2009
    ..These reports represent the first step toward an evidence-based approach to the prevention and management of these important effects...
  20. ncbi request reprint Oxaliplatin in tumors other than colorectal cancer
    P M Lorusso
    Wayne State University Karmanos Cancer Institute, Detroit, Michigan, USA
    Oncology (Williston Park) 14:33-7. 2000
    ..Ongoing and planned trials will evaluate the efficacy of oxaliplatin in other disease settings and combinations...
  21. doi request reprint Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan, USA
    Clin Cancer Res 17:6437-47. 2011
    ..Data from the phase III trials and other studies of T-DM1-containing agents are eagerly awaited...
  22. pmc Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin
    Ulka N Vaishampayan
    Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 16:3795-804. 2010
    ..Toxicity was assessed weekly, and response was evaluated every two cycles...
  23. doi request reprint Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential
    Patricia M LoRusso
    Eisenberg Center for Translational Therapeutics, Karmanos Cancer Center, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 71:193-202. 2013
    ..Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)...
  24. ncbi request reprint A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
    Elisabeth I Heath
    Wayne State University Karmanos Cancer Institute, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Invest New Drugs 26:59-65. 2008
    ..The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution...
  25. ncbi request reprint A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor
    Amin M Alousi
    Karmanos Cancer Institute, Wayne State University School of Medicine, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA
    Invest New Drugs 25:147-54. 2007
    ..Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD)...
  26. ncbi request reprint Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 11:6233-9. 2005
    ..We conducted a phase I trial, based on accelerated titration "2B" design, of BMS-247550 given as a 1-hour infusion every 3 weeks...
  27. pmc A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
    Elaina M Gartner
    Karmanos Cancer Institute, Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Breast Cancer Res Treat 131:933-7. 2012
    ..Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary. Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients...
  28. pmc Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097
    Jianmei Wu
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Clin Cancer Res 18:2066-79. 2012
    ..This study investigated RO4929097 binding in plasma and its implications for the pharmacokinetics and pharmacodynamics of this compound...
  29. pmc Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Elisabeth I Heath
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 68:703-12. 2011
    ..To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin...
  30. pmc Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience
    Elisabeth I Heath
    Division of Hematology and Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    J Biopharm Stat 19:414-23. 2009
    ..The theoretical advantages and disadvantages of both Phase I trial designs did not readily emerge in their actual application in clinical trials conducted at our institution...
  31. doi request reprint Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan, USA
    Clin Cancer Res 17:5774-82. 2011
    ....
  32. pmc Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies
    Priscila H Goncalves
    Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Invest New Drugs 26:347-54. 2008
    ..Due to cardiac toxicity occurring with both the parent compound, SR233377, as well as this analog, this series of agents was abandoned from further clinical development...
  33. ncbi request reprint Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 9:2040-8. 2003
    ..o. administered ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced cancer...
  34. ncbi request reprint Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    J Clin Oncol 26:3051-6. 2008
    ..This phase I study assessed the safety, optimally tolerated regimen (OTR), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of lapatinib and docetaxel in patients with advanced solid tumors...
  35. ncbi request reprint Clinical experience of MEK inhibitors in cancer therapy
    Ding Wang
    Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA
    Biochim Biophys Acta 1773:1248-55. 2007
    ..Several MEK inhibitors have been examined in early-phase clinical trials and the current state of clinical results using these therapies is presented here...
  36. doi request reprint Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 17:2502-11. 2011
    ..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed...
  37. ncbi request reprint A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer
    Maha Hussain
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State, University, Detroit, MI, USA
    Invest New Drugs 21:465-71. 2003
    ..We conducted a phase II trial to evaluate the efficacy and toxicity of this agent in patients with advanced renal cell cancer (RCC)...
  38. ncbi request reprint Phase I studies of ZD1839 in patients with common solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201 2097, USA
    Semin Oncol 30:21-9. 2003
    ..Based on the phase I study results, once-daily oral doses of 250 mg and 500 mg, which are well below the maximum tolerated dose, were selected for further clinical investigation of ZD1839...
  39. ncbi request reprint Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration
    Ramesh R Boinpally
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 110 East Warren, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 55:404-7. 2005
    ..To determine the oral bioavailability of R-XK469, a water-soluble investigational anticancer agent undergoing phase I clinical trials as an intravenous product...
  40. ncbi request reprint Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
    Basil F El-Rayes
    Division of Hematology Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI 48201, USA
    Invest New Drugs 23:57-62. 2005
    ..The purpose of this study was to determine the recommended phase II dose (RPTD) of the combination of cyclophosphamide and liposomal doxorubicin (Doxil)...
  41. ncbi request reprint Phase II study of CI-958 in colorectal cancer
    A F Shields
    Barbara Ann Karmanos Cancer Institute, Detroit Medical Center, Wayne State University, Michigan, USA
    Cancer Chemother Pharmacol 43:162-4. 1999
    ..We completed a phase II trial of CI-958 (NSC 635371) in patients with advanced colorectal cancer given at a dose of 700 mg/m2 every 21 days...
  42. ncbi request reprint The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be
    Ryan J Sullivan
    Authors Affiliations Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
    Clin Cancer Res 19:5283-91. 2013
    ..This overview presents the historical context to this therapeutic revolution, reviews the benefits and limitations of current therapies, and provides a look ahead at where the field is headed...
  43. ncbi request reprint Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Jeffrey L Evelhoch
    Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
    Clin Cancer Res 10:3650-7. 2004
    ..The aim of the study reported here was to assess the ability of dynamic contrast enhanced magnetic resonance imaging (MRI) to measure the antivascular effects of ZD6126 in tumors...
  44. doi request reprint Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future
    Elaina M Gartner
    Departments of Internal Medicine and daggerPharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
    Cancer J 16:83-90. 2010
    ..The most recent data from the clinical trials of olaparib (AZD2281, KU-0059436), BSI-201, AG014699, ABT-888, and INO-1001 and descriptions of ongoing studies are also presented...
  45. ncbi request reprint A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design
    S M Gadgeel
    Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Invest New Drugs 21:63-74. 2003
    ..8-8.4 mg/m2/d x 5. No significant correlation was observed between plasma levels and toxicity. No tumor responses were observed among the 14 patients evaluable for response...
  46. ncbi request reprint Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU)
    Patricia M LoRusso
    Karmanos Cancer Institute at Wayne State University School of Medicine, Department of Internal Medicine, Detroit, MI, USA
    Invest New Drugs 20:63-71. 2002
    ..Using an accelerated titration trial design with one patient cohorts and initial 100% escalations, a Phase I trial was conducted to determine the maximum tolerated dose (MTD) of 5FP and describe its toxicity and pharmacokinetic profile...
  47. ncbi request reprint The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways
    Z Ding
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Prentis Building, 110 East Warren, Detroit, MI 48201, USA
    Clin Cancer Res 7:3336-42. 2001
    ....
  48. ncbi request reprint Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond
    K A Keyes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 6:2474-81. 2000
    ..Pharmacology studies proved that protracted therapy causes little, if any, change in cellular drug tolerance or systemic exposure...
  49. ncbi request reprint Vascular disrupting agents
    M J Pilat
    Department of Internal Medicine, Division of Hematology Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    J Cell Biochem 99:1021-39. 2006
    ..More evidence suggests VDAs will have their greatest effect in combination with conventional chemotherapy or other modes of treatment that attack this outer rim of cells...
  50. ncbi request reprint Non-rash skin toxicities associated with novel targeted therapies
    Mario E Lacouture
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
    Clin Lung Cancer 8:S36-42. 2006
    ..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment...
  51. ncbi request reprint A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 13:3906-12. 2007
    ..Additionally, the pharmacokinetics and possible antitumor activity were studied...
  52. ncbi request reprint The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes
    Joel M Reid
    Department of Oncology and Mass Spectrometry Facility, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 10:1471-80. 2004
    ..PZA, 9-desmethyl-PZA, and PZA N-oxide inhibited growth of A375 human melanoma cells. IC(50) values were 0.17, 0.11, and 7.0 micro M, respectively, for the three molecules...
  53. ncbi request reprint In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis
    Donna A Volpe
    Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
    Cancer Chemother Pharmacol 54:89-94. 2004
    ....
  54. ncbi request reprint Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    John Rinehart
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Oncol 22:4456-62. 2004
    ....
  55. ncbi request reprint Differentiation and definition of vascular-targeted therapies
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, PO Box 100385, Gainesville, FL 32610, USA
    Clin Cancer Res 11:416-20. 2005
    ....
  56. ncbi request reprint Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions
    Lawrence W Anderson
    Food and Drug Administration, WO Bldg 64, Rm 2014, 10903 New Hampshire Avenue, HFD 902, Silver Spring, MD 20993, USA
    Cancer Chemother Pharmacol 56:351-7. 2005
    ..The multiday half-life of XK469 hampered our ability to obtain a complete mass balance, and the possibility exists that other routes, such as biliary excretion, may also play a substantial role in XK469 disposition...
  57. ncbi request reprint Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
    Patricia M LoRusso
    Barbara Ann Karmanos Cancer Institute Wayne State University, USA
    Expert Opin Investig Drugs 17:1013-28. 2008
    ..Since combination chemotherapy is most often required for optimal benefit, the potential benefit to combining targets in one agent is of considerable interest in drug development...
  58. doi request reprint Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 14:4186-91. 2008
    ..Pharmacokinetic sampling was done up to 72 hours after the first four doses and analyzed with a validated liquid chromatography/mass spectrometry assay...

Research Grants3

  1. Phase I Clinical Trials of New Anticancer Agents
    Patricia LoRusso; Fiscal Year: 2007
    ....